Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects

Completed · Phase 2

Conditions studied: Healthy Subjects

In brief

The purpose of this study is to see if a naturally-occurring hormone called erythropoietin changes the action of platelets in the blood. Erythropoietin is made by the kidneys to stimulate red blood cell production to prevent anemia. Platelets are small cells in the blood that help clot blood in case of injury. Platelets also sometimes form blood clots in blood vessels that may cause heart attacks. This study is trying to determine whether erythropoietin increases the clotting action of platelets. Information on erythropoietin in healthy subjects may eventually help in the treatment of patients with heart attacks.

Key facts

Study ID

NCT00368238

Run by

Yale University

People needed

96

Starts

2005-10-01

Expected to finish

2006-07-01

Last updated by the study team

2006-08-24

Who can join

Age: 21 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 21-40 years
• Able and willing to provide written informed consent
• Bleeding time <10 minutes

You may not qualify if…

• Any chronic medical disease
• Chronic or frequent over-the-counter or prescription medication use
• Hemoglobin >15 gm/dl for both genders or <13 gm/dl (men) or <12 gm/dl (women)
• Platelet count >400,000/µl or <150,000/µl
• Blood pressure > 140/90 mmHg

Where it is running

• Yale University School of Medicine — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.